COVID-19大流行对神经肿瘤学结局的影响
该回顾性研究比较2020年与2019年同期恶性脑肿瘤患者的诊疗变化与结局,共纳入2020年112例、2019年166例。2020年治疗延迟(p=0.0160)和远程医疗使用(p<0.0001)显著增加,但两队列结局无显著差异;2020年使用远程医疗者肿瘤控制更稳定(p=0.0124),与进展患者合理使用面诊一致。
要点
- 大流行期间远程医疗与选择性诊疗调整未导致不良结局。
- 2020年治疗延迟和远程医疗使用显著多于2019年。
- 使用远程医疗的患者肿瘤控制更稳定,提示合理分流。
核心结论
- 大流行期间使用远程医疗和选择性调整神经肿瘤诊疗未导致患者结局恶化,提示医生主导的适应性改变是成功的。
研究设计与样本
- 单中心回顾性研究,比较2020年3月13日至5月1日与2019年同期恶性脑肿瘤患者,2020年112例、2019年166例。
主要发现
- 两队列结局无显著差异;2020年治疗延迟显著更多(p=0.0160),远程医疗使用显著更多(p<0.0001)。
- 2020年使用远程医疗的患者肿瘤控制显著更稳定(p=0.0124),与进展患者合理使用面诊一致。
临床怎么用
- 可参考本研究在疫情等特殊时期采用远程医疗与选择性调整诊疗,但需合理保留进展患者的面诊。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: The Coronavirus disease 2019 (COVID-19) pandemic has uprooted healthcare systems worldwide, disrupting care and increasing dependence on alternative forms of health care delivery. It is yet to be determined how the pandemic affected neuro-oncology patient outcomes, given that the majority of even "elective" neurosurgical oncology procedures are time-sensitive. This study quantifies changes in neuro-oncological care during the height of the pandemic and investigates patient outcomes in 2020 compared to a historical control. METHODS: We performed a retrospective review of patients with malignant brain tumor diagnoses who were seen at our institution between March 13 and May 1 of 2020 and 2019. Alterations in care, including shift from in-person to telehealth, delays in evaluation and intervention, and treatment modifications were evaluated. These variables were analyzed with respect to brain tumor control and mortality. RESULTS: 112 patients from 2020 to 166 patients from 2019 were included. There was no significant difference in outcomes between the cohorts, despite significantly more treatment delays (p = 0.0160) and use of telehealth (p < 0.0001) in 2020. Patients in 2020 who utilized telehealth visits had significantly more stable tumor control than those who had office visits (p = 0.0124), consistent with appropriate use of in-person visits for patients with progression. CONCLUSIONS: Our study showed that use of telehealth and selective alterations in neuro-oncological care during the COVID-19 pandemic did not lead to adverse patient outcomes. This suggests that adaptive physician-led changes were successful and may inform management during the ongoing pandemic, especially with the emergence of the Delta variant.
引用
- Norman S, Ramos A, Giantini Larsen AM, et al. Impact of the COVID-19 pandemic on neuro-oncology outcomes. J Neurooncol. 2021. PMID: 34510329. doi:10.1007/s11060-021-03838-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。